Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia

Seminars in Hematology

Volumn 37, Issue 2 SUPPL. 4, 2000, Pages 28-34

  Vadhan Raj, Saroj ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; IFOSFAMIDE; NEUTRALIZING ANTIBODY; RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; RECOMBINANT THROMBOPOIETIN; THROMBOPOIETIN;

CANCER PATIENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG TOLERABILITY; HUMAN; MOLECULAR CLONING; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SOLID TUMOR; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0034074551     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0037-1963(00)90050-7     Document Type: Review

References (23)

1. S Vadhan-Raj AP Kudelka L Garrison Effects of interleukin-1α on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer J Clin Oncol 12 1994 707 714
2. V D'Hondt P Weynants Y Humblet Dose-dependent interleukin-3 stimulation of thrombopoiesis and neutropoiesis in patients with small-cell lung carcinoma before and following chemotherapy: A placebo-controlled randomized phase Ib study J Clin Oncol 11 1993 2063 2071
3. GD Demetri RM Bukowski B Samuels Stimulation of thrombopoiesis by recombinant human interleukin-6 (IL-6) pre-chemotherapy and postchemotherapy in previously untreated sarcoma patients with normal hematopoiesis Blood 82 suppl 1 1993 A367 abstr
4. S Vadhan-Raj NE Papadopoulos MA Burgess Effects of PIXY321, a granulocyte-macrophage colony-stimulating factor/interleukin-3 fusion protein, on chemotherapy-induced multilineage myelosuppression in patients with sarcoma J Clin Oncol 12 1994 715 724
5. I Tepler L Elias JW Smith II A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy Blood 87 1996 3607 3614
6. TD Bartley J Bogenberger P Hunt Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl Cell 77 1994 1117 1124
7. FJ de Sauvage PE Hass SD Spencer Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand Nature 369 1994 533 538
8. DJ Kuter DL Beeler RD Rosenberg The purification of megapoietin: A physiological regulator of megakaryocyte growth and platelet production Proc Nad Acad Sci USA 91 1994 11104 11108
9. S Lok K Kaushansky RD Holly Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo Nature 369 1994 565 568
10. F Wendling E Maraskovsky N Debili cMpl ligand is a humoral regulator of megakaryocytopoiesis Nature 369 1994 571 574
11. S Vadhan-Raj LJ Murray C Bueso-Ramos Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer Ann Intern Med 126 1997 673 681
12. M Fanucchi J Glaspy J Crawford Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer N Engl J Med 336 1997 404 409
13. RL Basser JEJ Rasko K Clarke Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer Blood 89 1997 3118 3128
14. RL Basser JEJ Rasko K Clarke Erratum Blood 90 1997 2513
15. S Vadhan-Raj S Patel HE Broxmeyer Phase I–II investigation of recombinant human thrombopoietin (rhTPO) in patients with sarcoma receiving high dose chemotherapy (CT) with adriamycin (A) and ifosfamide (I) Blood 88 suppl 1 1996 448a abstr 1779
16. S Vadhan-Raj Recombinant human thrombopoietin: clinical experience and in vivo biology Semin Hematol 35 1998 261 268
17. S Vadhan-Raj S Patel H Broxmeyer Schedule-dependent reduction in thrombocytopenia by recombinant human thrombopoietin (rhTPO) in patients with sarcoma receiving high dose chemotherapy (CT) with Adriamycin (A) and ifosfamide (I) Proc Am Soc Clin Oncol 18 1999 52a (abstr 193)
18. S Vadhan-Raj DF Verschraegen C Bueso-Ramos Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer Ann Intern Med 132 1900 364 368
19. J Crawford J Glaspy C Belani A randomized, placebo-controlled, blinded, dose scheduling trial of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) with filgrastim support in non-small cell lung cancer (NSCLC) patients treated with paclitaxel and carboplatin during multiple cycles of chemotherapy Proc Am Soc Clin Oncol 17 1998 73a (abstr 285)
20. C Yang Y Xia J Li DJ Kuter The appearance of anti-thrombopoietin antibody and circulating thrombopoietin-IgC complexes in a patient developing thrombocytopenia after the injection of PEG-rHuMGDF Blood 94 suppl 1 1999 681a abstr 3014
21. ®, Sept 11, 1998
22. S Vadhan-Raj LM Currie C Bueso-Ramos Enhanced retention of in vitro functional activity of platelets from recombinant human thrombopoietintreated patients following long-term cryopreservation with a platelet-preserving solution (ThromboSol) and 2% DMSO Br J Haematol 104 1999 403 411
23. DJ Kuter The use of PEG-rHuMGDF in platelet apheresis Stem Cells 16 suppl 2 1998 231 242